Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: A prospective, observational, international, multi-centre study
| العنوان: | Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: A prospective, observational, international, multi-centre study |
|---|---|
| المؤلفون: | Peter J Jongen, Dirk Lehnick, Evert Sanders, Pierrette Seeldrayers, Sten Fredrikson, Magnus Andersson, Joachim Speck, Focus Study group |
| المصدر: | Health and Quality of Life Outcomes Health and Quality of Life Outcomes, Vol 8, Iss 1, p 133 (2010) |
| بيانات النشر: | Zenodo, 2010. |
| سنة النشر: | 2010 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Psychometrics, medicine.medical_treatment, lcsh:Computer applications to medicine. Medical informatics, Multiple Sclerosis, Relapsing-Remitting, Quality of life, Surveys and Questionnaires, Internal medicine, medicine, Humans, Prospective Studies, Glatiramer acetate, Prospective cohort study, Qualitative Research, Depression (differential diagnoses), Dose-Response Relationship, Drug, business.industry, Research, Multiple sclerosis, Public Health, Environmental and Occupational Health, Immunosuppression, Glatiramer Acetate, Interferon-beta, General Medicine, medicine.disease, humanities, Relapsing remitting, Quality of Life, Physical therapy, lcsh:R858-859.7, Female, Observational study, Peptides, business, Immunosuppressive Agents, medicine.drug |
| الوصف: | BACKGROUND Glatiramer acetate (GA) and interferon-beta (INFb) are first-line disease modifying drugs for relapsing remitting multiple sclerosis (RRMS). Treatment with INFb is associated with a significant increase in health-related quality of life (HR-QoL) in the first 12 months. It is not known whether HR-QoL increases during treatment with GA. METHODS 197 RRMS patients, 106 without and 91 with prior immunomodulation/immunosuppression, were studied for HR-QoL (Leeds Multiple Sclerosis-QoL [LMS-QoL] scale, score range 0 - 32), fatigue (Fatigue Impact Scale [FIS]) and depressed mood (Beck Depression Inventory-Short Form [BDI-SF]) at baseline and 6 and 12 months after start of GA treatment. RESULTS At 6 and 12 months mean LMS-QoL scores were significantly increased in the treatment-naive patient group (p textless 0.001), not in the pre-treated group. At month 12 43% of treatment-naïve patients had improved HR-QoL (increase LMS-QoL score 3 or more points) (p textless 0.001). Likewise, mean FIS scores were decreased at months 6 and 12 in the treatment-naïve group (p textless 0.01), not in the pre-treated group. In both groups mean BDI-SF scores did not change. No demographic or clinical baseline factor was predictive of HR-QoL increase. HR-QoL changes were zero to negative for patients who had discontinued GA before month 12 (28.4% of patients). CONCLUSIONS In RRMS patients without prior immunomodulation/immunosuppression treatment with GA was associated with an increase in HR-QoL in the first 6 months, that was sustained at 12 months. In 4 out of 10 patients HR-QoL improved. Increase in HR-QoL was associated with decrease in fatigue. + ID der Publikation: unilu_29634 + Sprache: Englisch + Letzte Aktualisierung: 2021-02-22 13:04:58 |
| DOI: | 10.5281/zenodo.4555325 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73e4f80adb21958ec2b8f19a1adbef72Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....73e4f80adb21958ec2b8f19a1adbef72 |
| قاعدة البيانات: | OpenAIRE |
| DOI: | 10.5281/zenodo.4555325 |
|---|